Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

SIMPLE SUMMARY: Preclinical analyses identified APR-246 as a potent treatment option for neuroblastoma. However, a specific mode of action, sufficient biomarkers and promising combination partners are still missing. Here, we analyze the susceptibilities of different entities and relate them to gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Michael, Rösch, Lisa, Najafi, Sara, Gatzweiler, Charlotte, Ridinger, Johannes, Gerloff, Xenia F., Jones, David T. W., Baßler, Jochen, Kreth, Sina, Stainczyk, Sabine, Frese, Karen, Meder, Benjamin, Westermann, Frank, Milde, Till, Peterziel, Heike, Witt, Olaf, Oehme, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431508/
https://www.ncbi.nlm.nih.gov/pubmed/34503286
http://dx.doi.org/10.3390/cancers13174476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431508/
https://www.ncbi.nlm.nih.gov/pubmed/34503286
http://dx.doi.org/10.3390/cancers13174476

Ejemplares similares